Walt Disney’s earnings beat Wall Street estimates, Super Micro Computer extends losses, and Cisco posts fiscal first-quarter ...
Health and wellness platform Hims & Hers Health, Inc. (NYSE:HIMS), which has gained traction for its obesity-related ...
Hims & Hers (HIMS) fell 22% after Amazon (AMZN) announced it was entering the hair loss and erectile dysfunction treatment ...
Hims & Hers once again delivered a blowout quarter with surging revenue. Revenue soared 77% year over year to $401.6 million, ...
Citi analyst Daniel Grosslight has maintained their neutral stance on HIMS stock, giving a Hold rating on November 6. Daniel ...
Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.
The tech giant said it would offer upfront, monthly pricing for customers seeking consultations and medications for five ...
Last week, Hims & Hers Health (NYSE:HIMS) dropped another mic with its latest earnings, and the numbers are mind-blowing.
Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's ...
BofA analyst Allen Lutz downgraded Hims & Hers to Underperform from Buy. Published first on TheFly – the ultimate source for ...